此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

了解多发性骨髓瘤或 CD19+ 淋巴细胞增殖性疾病 (LPD) CAR-T 治疗后克隆和非克隆血细胞减少的机制

2026年9月30日 更新者:Mayo Clinic

了解 CAR-T 疗法后克隆和非克隆血细胞减少的机制

This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric antigen receptor T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients experience cytopenia that last longer than 30 days post-infusion. Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic/genomic testing is a series of tests that find specific changes in cancer cells or in blood deoxyribonucleic acid. Identifying gene mutations may help identify the risk of cytopenia in patients with multiple myeloma or CD19 positive LPD following CAR-T therapy.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. Determine the preexisting and therapy-emergent germline and somatic variants associated with an increased risk of clonal and non-clonal cytopenia following CAR-T cell therapy on research basis.

SECONDARY OBJECTIVE:

I. Characterize the baseline transcriptomic signature associated with non-clonal and clonal cytopenia following CAR-T therapy on research basis.

OUTLINE:

Patients undergo bone marrow aspiration and hair, saliva, buccal swab, or skin sample collection up to 14 days prior to lymphodepleting (LD) therapy. Patients undergo clinical follow-up (CFU) on day 90 post-CAR-T therapy. Patients with unexplained cytopenia also undergo bone marrow aspiration for sequencing analysis on day 90 and at development of myeloid neoplasm post-cytotoxic therapies (MN-pCT) during CFU. Patients also undergo bone marrow aspiration at determination of clonal evolution or myeloid neoplasm if not done during CFU on day 90.

Patients with unexplained cytopenia at day 90 are followed up every 90 days for up to 2 years until resolution. Patients without unexplained cytopenia are followed clinically for up to 2 years.

研究类型

介入性

注册 (估计的)

82

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Arizona
      • Scottsdale、Arizona、美国、85259
        • 招聘中
        • Mayo Clinic in Arizona
        • 接触:
        • 首席研究员:
          • Cecilia Y. Arana Yi, MD
    • Florida
      • Jacksonville、Florida、美国、32224-9980
        • 招聘中
        • Mayo Clinic in Florida
        • 接触:
        • 首席研究员:
          • Talha Badar, MD
    • Minnesota
      • Albert Lea、Minnesota、美国、56007
        • 招聘中
        • Mayo Clinic Health System in Albert Lea
        • 接触:
        • 首席研究员:
          • Mina S. Hanna, MD
      • Mankato、Minnesota、美国、56001
        • 招聘中
        • Mayo Clinic Health System-Mankato
        • 接触:
        • 首席研究员:
          • Amrit B. Singh, MBBS
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic in Rochester
        • 接触:
        • 首席研究员:
          • Mithun V. Shah, MD, PhD
    • Wisconsin
      • Eau Claire、Wisconsin、美国、54701
        • 招聘中
        • Mayo Clinic Health System-Eau Claire Clinic
        • 接触:
        • 首席研究员:
          • Eyad S. Al-Hattab, MD
      • La Crosse、Wisconsin、美国、54601
        • 招聘中
        • Mayo Clinic Health System-Franciscan Healthcare
        • 接触:
        • 首席研究员:
          • Scott H. Okuno, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥ 18 years
  • Histologically or cytologically confirmed diagnosis of multiple myeloma (MM) as defined in International Myeloma Working Group (IMWG) criteria or a CD19+ lymphoproliferative disorder (LPD) as defined by 2016 World Health Organization (WHO) classification
  • Provide written informed consent
  • Willingness to provide mandatory bone marrow aspirate specimens for correlative research. All bone marrow aspirate samples are collected during a clinical procedure
  • Willingness to provide mandatory hair follicle or skin punch biopsy specimens (skin punch biopsy specimens will be obtained from Mayo Clinic Rochester patients only) for correlative research
  • Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
  • Willingness to provide mandatory saliva or buccal swab sample for correlative research

Exclusion Criteria:

  • Ineligible for CAR-T therapy
  • Patients diagnosed with myeloid neoplasm before CAR-T therapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Supportive care (bone marrow aspiration, CFU)

Patients undergo bone marrow aspiration and hair, saliva, buccal swab, or skin sample collection up to 14 days prior to LD therapy. Patients undergo CFU on day 90 post-CAR-T therapy. Patients with unexplained cytopenia also undergo bone marrow aspiration for sequencing analysis on day 90 and at development of MN-pCT during CFU. Patients also undergo bone marrow aspiration at determination of clonal evolution or myeloid neoplasm if not done during CFU on day 90.

Undergo bone marrow aspiration

Ancillary studies

Undergo hair, buccal, and saliva sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Undergo CFU

其他名称:
  • 主动跟进
  • 临床体征随访
  • CLSFUP
  • 跟进
  • 已关注

Receive genetic counselor consultation

Undergo sequencing analysis

其他名称:
  • 基因检查
  • 基因检测
  • 基因分析

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Pathogenic and likely pathogenic germline and somatic variants associated with increased risk
大体时间:At baseline

The count and percentage of patients with the presence of somatic or germline variants will be reported. The number, type, and function of somatic variants will also be reported.

At baseline
Unexplained cytopenia
大体时间:At day 90

Unexplained cytopenia will be defined per World Health Organization (WHO)-5 as a combination of any of the following: hemoglobin < 12 g/dL in females, hemoglobin < 13 g/dL in males, absolute neutrophil count < 1.8 x 10^9/L and platelets < 150 x 10^9/L. Logistic regression will be used to identify the presence or absence of baseline germline and somatic mutations associated with unexplained cytopenia. An odds ratio and 95% confidence interval will be reported.

At day 90

次要结果测量

结果测量
措施说明
大体时间
Development of myeloid neoplasm post-cytotoxic therapies (MN-pCT)
大体时间:Up to 2 years

Assessed as development of MN-pCT at any time following CAR-T infusion. MN-pCT is defined per The World Health Organization- Five Well-Being Index (WHO-5). The count and percentage of patients with the presence of somatic or germline variants will be reported. The number, type, and function of somatic variants will also be reported.

Up to 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Mithun V. Shah, MD、Mayo Clinic in Rochester

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年11月22日

初级完成 (估计的)

2029年12月16日

研究完成 (估计的)

2031年12月16日

研究注册日期

首次提交

2024年10月3日

首先提交符合 QC 标准的

2024年10月3日

首次发布 (实际的)

2024年10月8日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅